Loading…
CRISPR Therapeutics AG is projected to rise to $63.00 by 2027, a +18% move from its current price of $53.53. CRSP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $52.09 | $53.56 | $55.07 | +0.05% |
| May 30 | $51.52 | $53.58 | $55.73 | +0.10% |
| May 31 | $51.09 | $53.61 | $56.25 | +0.15% |
| Jun 1 | $50.74 | $53.64 | $56.70 | +0.20% |
| Jun 2 | $50.43 | $53.66 | $57.10 | +0.25% |
| Jun 3 | $50.16 | $53.69 | $57.47 | +0.30% |
| Jun 4 | $49.91 | $53.72 | $57.82 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $49.91 | $53.72 | $57.82 | +0.35% |
| Week 2 | $48.58 | $53.91 | $59.81 | +0.70% |
| Week 3 | $47.63 | $54.09 | $61.44 | +1.05% |
| Week 4 | $46.86 | $54.28 | $62.88 | +1.41% |
| Week 5 | $46.22 | $54.47 | $64.21 | +1.76% |
| Week 6 | $45.66 | $54.66 | $65.45 | +2.12% |
| Week 7 | $45.16 | $54.86 | $66.63 | +2.48% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CRISPR Therapeutics AG is a healthcare company that focuses on developing gene-based medicines using its CRISPR/Cas9 platform. Its work spans a portfolio of programs across disease areas such as hemoglobinopathies, CAR T cell therapies, in vivo gene editing, and autoimmune indications.
The lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating transfusion-dependent beta-thalassemia, severe sickle cell disease, and related hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320 for in vivo gene editing addressing cardiovascular targets, and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for type 1 diabetes. The company has strategic partnerships with Vertex Pharmaceuticals Incorporated and was incorporated in 2013, headquartered in Zug, Switzerland.
CRISPR Therapeutics AG (CRSP) is a healthcare stock with a current price of $50.36 and a market capitalization of $4.86B, ranking 1365 in market cap terms. The stock trades within a 30-day range of $41.88 to $60.56, reflecting near-term volatility around the mid-$50s.
The year-by-year forecast presents an ascending path for the average price, starting at $50.36 in 2026 and climbing to $89.67 by 2030, then $165.36 by 2040 and $318.20 by 2050, with corresponding ROI figures of 0% in 2026, rising to 78.1% in 2030 and 531.9% by 2050. Near-term technicals show bearish sentiment, while longer horizons reflect a bullish tilt as the forecasts extend further out. RSI is 50, with a SMA50 of $51.02 and SMA200 of $55.74, and price support and resistance at $47.59 and $57.99 respectively.
A major floor 20.3% below — a decisive break under it would weaken the trend.
The nearest floor, 11.1% below — buyers have tended to step in here.
The nearest ceiling, 8.3% above — a clean break opens room to run.
A major ceiling 18.5% above — clearing it would confirm fresh momentum.
Key CRSP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRSP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $50.79 | Buy | $51.39 | Buy |
| MA 10 | $50.17 | Buy | $51.03 | Buy |
| MA 20 | $51.58 | Buy | $51.37 | Buy |
| MA 50 | $51.18 | Buy | $51.92 | Buy |
| MA 100 | $52.60 | Buy | $52.72 | Buy |
| MA 200 | $55.71 | Sell | $53.05 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.40 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 72.13 | Neutral |
| Williams %R (14) | -17.96 | Info |
| MACD (12,26,9) | 0.10 | Buy |
| ROC (12) | -2.37 | Sell |
| Bollinger %B (20,2) | 0.73 | Neutral |
| Stochastic %K (14) | 82.04 | Sell |
| TRIX (15) | -0.14 | Sell |
| Awesome (5,34) | -1.96 | Sell |
| Ultimate (7,14,28) | 69.18 | Neutral |
| Momentum (10) | 0.70 | Buy |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 52.13 | Buy |
| ADX (14) | 10.48 | Neutral |
| ATR (14) | 1.41 | Info |
The 30-day technical picture leans toward neutral to bearish sentiment, with RSI(14) at 50. The stock trades around the mid-$50s, with the SMA50 at $51.02 and the SMA200 at $55.74, suggesting near-term tendencies to hover around or drift toward the longer-term moving average.
Key near-term levels include support at $47.59 and resistance at $57.99. The 30-day price range extends from $41.88 to $60.56, highlighting the volatility within the coming month and the potential for swings around the current price level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $44.34 | $53.53 | $68.83 | 0% | Neutral | |
| $49.88 | $63.00 | $84.35 | +18% | Neutral | |
| $58.25 | $75.63 | $105.00 | +41% | Bullish | |
| $66.97 | $89.00 | $127.14 | +66% | Bullish | |
| $74.20 | $100.65 | $147.31 | +88% | Bullish | |
| $72.13 | $99.70 | $149.05 | +86% | Bullish | |
| $74.49 | $104.79 | $159.67 | +96% | Bullish | |
| $81.21 | $116.13 | $180.04 | +117% | Bullish | |
| $87.13 | $126.58 | $199.38 | +136% | Bullish | |
| $102.61 | $151.31 | $241.90 | +183% | Bullish | |
| $126.73 | $200.10 | $340.38 | +274% | Bullish | |
| $218.52 | $388.30 | $723.13 | +625% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $44.34 | $53.53 | $62.86 | +0.00% |
| June 2026 | $46.76 | $54.93 | $66.09 | +2.62% |
| July 2026 | $47.28 | $56.03 | $68.33 | +1.99% |
| August 2026 | $46.09 | $54.98 | $67.76 | -1.86% |
| September 2026 | $46.02 | $55.20 | $68.62 | +0.40% |
| October 2026 | $47.13 | $56.83 | $71.19 | +2.94% |
| November 2026 | $46.33 | $56.11 | $70.76 | -1.26% |
| December 2026 | $44.58 | $54.23 | $68.83 | -3.35% |
Click any year to see its month-by-month CRSP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
CRISPR Therapeutics AG's 2026 outlook centres on $53.53, within a $44.34 to $68.83 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CRSP could reach as high as $84.35, with a base case around $63.00 and support toward $49.88 — roughly +18% from $53.53. Price action looks broadly range-bound.
Expect CRSP to range from $58.25 to $105.00 through 2028. The $75.63 average target implies a +41% move from current prices. That is up +20% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CRSP price prediction for 2029 points to an average of $89.00 (low $66.97, high $127.14) — a potential gain of +66% on today's $53.53. Momentum favours further upside here.
In 2030, CRSP is projected to trade between $74.20 and $147.31, averaging $100.65 — a potential gain of +88% from today's $53.53. That is up +13% on the projected 2029 average. Buyers look set to stay in control over this stretch.
CRISPR Therapeutics AG's 2031 outlook centres on $99.70, within a $72.13 to $149.05 range. That is -1% versus the projected 2030 average. That marks a +86% change versus current levels. Momentum favours further upside here.
By 2032, CRSP could reach as high as $159.67, with a base case around $104.79 and support toward $74.49 — roughly +96% from $53.53. Buyers look set to stay in control over this stretch.
Expect CRSP to range from $81.21 to $180.04 through 2033. The $116.13 average target implies a +117% move from current prices. That is up +11% on the projected 2032 average. Momentum favours further upside here.
The CRSP price prediction for 2034 points to an average of $126.58 (low $87.13, high $199.38) — a potential gain of +136% on today's $53.53. Buyers look set to stay in control over this stretch.
In 2035, CRSP is projected to trade between $102.61 and $241.90, averaging $151.31 — a potential gain of +183% from today's $53.53. That is up +20% on the projected 2034 average. Momentum favours further upside here.
CRISPR Therapeutics AG's 2040 outlook centres on $200.10, within a $126.73 to $340.38 range. That is up +32% on the projected 2035 average. That marks a +274% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CRSP could reach as high as $723.13, with a base case around $388.30 and support toward $218.52 — roughly +625% from $53.53. Momentum favours further upside here.
Investing $1,000 in CRSP today (≈ 18.681113 CRSP) could be worth
$7,253.92
+$6,253.92 (+625%) by 2050 · US Dollar
Based on the average projected CRSP price of $388.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRSPwould be worth at today's price.
$1,000 invested in CRSP on May 27, 2025 (≈ 26.616982 CRSP) would be worth
$1,424.81
+$424.81 (+42.5%) today · 1.42× · US Dollar
Based on a CRSP entry price of $37.57 vs. today's $53.53.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $48.55 | $1,102.57 | +10.3% |
| 1 month ago | $50.99 | $1,049.81 | +5.0% |
| 3 months ago | $61.74 | $867.02 | -13.3% |
| 6 months ago | $53.47 | $1,001.12 | +0.1% |
| 1 year ago | $37.57 | $1,424.81 | +42.5% |
| All time (5.0y) ago | $115.8 | $462.26 | -53.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRSP forecast.
Our base-case forecast reaches $110.00 around 2033.
Implied market cap at $110.00: $10.61B
The multi-year forecast shows a clear bullish trajectory after 2026, with the average price advancing from $50.36 in 2026 to $89.67 in 2030 and then to $165.36 in 2040 before reaching $318.20 in 2050. The corresponding ROI rises from 0% in 2026 to 78.1% in 2030, 228.4% by 2040, and 531.9% by 2050, signaling substantial long-term upside potential.
By 2031–2035 the averages stay in a bullish range, with 2031 at $87.41, 2032 at $91.51, 2033 at $100.91, 2034 at $107.11, and 2035 at $128.61, all carrying bullish sentiment. The forecast continues to imply strong upside through 2040 and 2050, with 2040 and 2050 showing the highest expected gains. These are estimates, not guarantees, and actual results depend on market conditions and clinical/regulatory progress.
Tap a question to reveal the answer.
2030 forecast: min $66.00, average $89.67, max $131.47; ROI 78.1%; sentiment BULLISH.
The long-term forecast shows rising averages—for example, $50.36 in 2026, $89.67 in 2030, and $318.20 in 2050—with ROIs up to 531.9% by 2050, but near-term sentiment is mixed and outcomes are uncertain.
Yes. The 2033 forecast shows an average of $100.91 with a max of $156.75, indicating a path that crosses above $100.
For 2026, the min is $44.34, the average is $50.36, and the max is $64.08.
2050 forecast: min $178.37, average $318.20, max $594.18; ROI 531.9% with a bullish sentiment.
CRISPR Therapeutics AG Community Discussion
0Share your CRISPR Therapeutics AG price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.